Table 2

Baseline clinical characteristics of people with systemic autoimmune rheumatic diseases with confirmed COVID-19, overall and stratified by resolved or prolonged symptom duration by US Centers for Disease Control and Prevention definition of 28 days or longer (n=441)

Overall
N=441
Symptoms resolved in <28 days N=334Prolonged symptom duration 28 days or longer (active or resolved) N=107
SARD type
 Rheumatoid arthritis174 (39.5)139 (41.6)35 (32.7)
 Systemic lupus erythematosus69 (15.6)55 (16.5)14 (13.1)
 Myositis51 (11.6)38 (11.4)13 (12.1)
 Sjögren’s syndrome51 (11.6)36 (10.8)15 (14)
 Spondyloarthritis, other than psoriatic arthritis50 (11.3)33 (9.9)17 (15.9)
 Systemic vasculitis32 (7.3)24 (7.2)8 (7.5)
 Psoriatic arthritis31 (7.0)26 (7.8)5 (4.7)
 Systemic sclerosis18 (4.1)16 (4.8)2 (1.9)
 Other connective tissue disease*15 (3.4)11 (3.3)4 (3.7)
 Antiphospholipid syndrome11 (2.5)7 (2.1)4 (3.7)
 Autoinflammatory disease4 (0.9)3 (0.9)1 (0.9)
 Sarcoidosis2 (0.5)2 (0.6)0 (0)
Comorbidity count, mean (SD)4.5 (2.5)4.3 (2.5)5.0 (2.4)
Individual comorbidities
 Hypertension117 (26.5)79 (23.7)38 (35.5)
 Obesity102 (23.1)71 (21.3)31 (29.0)
 Lung disease†80 (18.1)55 (16.5)25 (23.4)
 Fibromyalgia51 (11.6)35 (10.5)16 (15.0)
 Osteoarthritis35 (7.9)21 (6.3)14 (13.1)
 Diabetes28 (6.3)20 (6.0)8 (7.5)
 Cardiovascular disease17 (3.9)10 (3.0)7 (6.5)
 No comorbidity145 (32.9)120 (35.9)25 (23.4)
  • N (%) are presented.

  • *Other connective tissue disease includes mixed connective tissue disease and undifferentiated connective tissue disease.

  • †Lung disease includes asthma, emphysema, chronic bronchitis, chronic obstructive pulmonary disease, pulmonary hypertension, interstitial lung disease, idiopathic pulmonary fibrosis and other lung diseases.

  • SARD, systemic autoimmune rheumatic disease.